(49) revealed that GLP-1 agonists significantly reduced the risk of HF in patients with T2D (RR 0.89, 95% CI 0.82 to 0.98), whereas Qin and Song (50) reported that they reduced the risk of nonfatal stroke (RR 0.85; 95% CI 0.77 to 0.94). This evidence concerns the gene GCG and Stroke.